Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT01487863 is registered in ClinicalTrials.gov with Dendreon as lead sponsor.

NCT NCT01487863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01487863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Lead sponsor
Dendreon
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
June 30, 2016
Enrollment
69 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, hormone refractory prostate cancer, prostate cancer metastatic